Bruce Berkowitz of the Fairholme Fund held a conference call on March 30 which focused on their investment in Pfizer. A replay of the call can be found here:
Pfizer CEO Jeffrey Kindler will join Bruce Berkowitz, Fairholme Capital Management’s Chief Investment Officer, for a Conversation with Bruce on Monday, March 30th, at 3:00 PM Eastern Time. We’ll also have Charles Fernandez, President of Fairholme Capital Management and an authority on corporate restructurings and the healthcare industry, bring his unique viewpoint to the discussion.
Bruce and Charlie will discuss the Fund’s leap into cash-rich companies in industries that are generally regarded as recession-resistant, like healthcare, defense and infrastructure. We’ll review some fundamentals and learn why they believe these new holdings can deliver the returns that Fairholme investors expect – even when pitted against a severe deflationary environment.
Pfizer, the world’s largest research-based pharmaceutical company, has recently taken on the mantle of Fairholme’s anchor holding, representing nearly 19% of our portfolio’s assets. Our panel will present Fairholme’s compelling investment case for Pfizer, including findings related to its stock valuation, healthcare demographics and regulatory issues.
Pfizer’s Jeff Kindler will take questions and discuss the unfolding merger with Wyeth, which will create one of the most diversified companies in the global healthcare industry.
If you have questions about Pfizer, or any other position in The Fund’s portfolio, submit them to firstname.lastname@example.org well in advance of the call, and Bruce, Charlie or Jeff will try to answer you on air. Or call in during the conference for your chance to join the conversation.
You have two ways to participate – by internet or phone. Go to www.fairholmefunds.com at the appointed time to hear the live audio stream.